Pediatric IBD Studies Should Assess Disease Activity, Panel Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Clinicians tell FDA that focusing solely on symptoms as an endpoint for pediatric ulcerative colitis and Crohn’s disease ignores the long-term deleterious effects of inflammation. Panel stresses the need to include growth as an endpoint and to conduct pediatric studies earlier.
You may also be interested in...
FDA Ulcerative Colitis Guidance: 'Ideal' Vision Vs. Practical Interim Approach
Agency favors assessments of signs/symptoms and endoscopy findings using well-defined and reliable patient- and clinician-reported outcomes instruments; since these don't exist, FDA will allow tweaking of existing assessment tools in the interim.
Would Sponsors Do Earlier Pediatric IBD Studies With Nod From Agency Or Advisory Committee?
Including adolescents in adult studies was one option for obtaining information on inflammatory bowel disease therapies’ efficacy and safety in children discussed at a two-day FDA and professional society workshop.
Gastroenterology Endpoints For IBD Drugs Once Again In FDA Spotlight
FDA is holding another workshop to discuss selection of endpoints in development of drugs to treat pediatric and adult inflammatory bowel diseases; the agency held four gastroenterology workshops last year.